美股三大指数集体收涨，道指涨0.04%，纳指涨0.9%，标普500指数涨0.47%，大型科技股多数上涨，甲骨文涨超9%，微软、博通涨超3%，英伟达、Meta涨 超2%。加密矿企、贵金属、有色金属涨幅居前，Vista黄金涨超14%，Hut 8涨超7%，泛美白银涨超6%，美国铝业公司、皇家黄金涨超5%，南方铜业涨超 4%。百货公司、保险经纪跌幅居前，梅西百货、柯尔百货跌超5%，美国再保险集团跌超2%。 纳斯达克中国金龙指数收涨0.12%，热门中概股里，金山云、小马智行、晶科能源、文远知行至多涨3.79%，再鼎医药涨2.44%，华住涨1.66%，百度、网 易、阿里巴巴至少涨0.3%，百胜中国跌0.78%，小鹏跌1.02%，携程跌1.38%，B站跌2.41%，蔚来跌2.98%，理想跌3.27%，新东方跌4.24%。 ...

2月9日，美股三大指数集体低开，纳指跌0.37%，道指跌0.21%，标普500指数跌0.26%。 大型科技股涨跌不一，闪迪跌超4%，超威半导体跌近2%；甲骨文涨近5%。 | 名称 | 涨跌幅 现价 | | --- | --- | | 道琼斯工业平均 | -0.21% 50008.58 | | 纳斯达克指数 | -0.37% 22945.34c | | 标普500 | -0.26% 6914.06 | 热门中概股集体下跌，纳斯达克中国金龙指数跌0.7%，理想汽车、哔哩哔哩、新东方、蔚来跌超 3%，携程集团、百度集团、腾讯音乐、京东集团跌超1%。 | 名称 | 涨跌幅 ▲ | 现价 | | --- | --- | --- | | 理想汽车 | -3.80% | 18.250 | | 昨週歩1 | -3.30% | 30.490 | | 新东方 | -3.30% | 60.650 | | 劇来 | -3.08% | 4.885 | | 搜狐 | -2.57% | 15.939 | | 携程集团 | -1.95% | 58.240 | | 百度集团 | -1.64% | 143.540 | | 小马智行 | -1.3 ...

智通财经APP获悉，香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方- S(09901)144.12万股，每股作价49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88 亿股，最新持股比例为10.96%。 ...

香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方-S(09901)144.12万股，每股作价 49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88亿股，最新持股比例为 10.96%。 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

新力量 New Force 第一上海研究部 research@firstshanghai.com 总第 4960 期 2026 年 2 月 6 日 星期五 研究观点 【公司研究】 新东方（EDU.US/9901.HK）FY26Q2 业绩表现超预期，全年收入指引上调 【公司评论】 四环医药(460.HK）：仿制药触底中，轩竹生物成功分拆，创新药进入收获期，惠升生 物布局糖尿病全管线也迎来成果兑现，医美肉毒素和新品大品种带动高速增长 评级变化 | 公司 | 评级 代码 | 目标价(港元） | | 2025年EPS(港元) | | | 2026年EPS(港元) | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 新 旧 | 新 旧 | 变动 | 新 | 旧 | 变动 | 新 | 旧 | 变动 | | 新东方（美元） | EDU 买入 买入 78.00 | 74.50 | 5% | 0.230 | 0.230 | 0% | 0.310 | 0.300 | 3% | 第一上海证券有限公司 香港中环德辅道中 71 号永安集团大厦 ...

格隆汇2月5日｜纳斯达克金龙中国指数盘初涨幅扩大至1.21%。 热门中概股蔚来涨7.4%，名创优品涨 5.4%，百胜中国涨3.4%，理想涨2.8%，中通快递、再鼎医药、B站、百度、金山云涨超2%，阿里巴巴 涨0.7%，小马智行跌1.2%，新东方跌2.8%。 ETF中，KWEB涨1.14%，CQQQ涨0.7%，ASHR跌0.1%， ASHS跌1.3%。 ...

来源：中国网 2月3日，2025年"中国大学生自强之星"活动分享会在北京交通大学科学会堂举行。本次活动由共青团中 央基层建设部指导，中国青年报社、中国青少年发展基金会主办，新东方教育科技集团协办，聚焦立德 树人根本任务，深入挖掘在爱国奉献、道德弘扬、科技创新、自主创业、志愿公益、身残志坚、自立自 强等方面事迹突出的新时代大学生先进典型，树立青年榜样。本年度共产生1000名"中国大学生自强之 星"个人及100个"中国大学生自强之星科创团体"。 "中国大学生自强之星"评选活动于2007年启动，新东方先后共出资1亿元，在全国范围内寻访青年榜 样。十八年来，活动共产生1.5万余名"中国大学生自强之星"。值得一提的是，自2024年度首次增设"科 创团体"类别以来，该类别累计获奖团体已达200个。他们与个人获奖者共同构建起更为立体、多元的青 年榜样群像，展现出新时代大学生在科技创新与团队协作中的蓬勃朝气与担当精神。 分享会伊始，北京交通大学党委常委、副校长李国岫在致辞中指出，自强的学子"用很真实的奋斗诠释 着新时代青年的优秀"，他们将自信、自立、自强内化为人生信条，将个人奋斗融入了时代洪流。他强 调，学校通过"将外在的资 ...

For those looking to find strong Consumer Discretionary stocks, it is prudent to search for companies in the group that are outperforming their peers. Has New Oriental Education (EDU) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.New Oriental Education is a member of the Consumer Discretionary sector. This group includes 257 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank includes 16 different groups a ...